- Home
- TBLD vs PRTA Comparison
TBLD vs PRTA Comparison
Compare TBLD & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TBLD | PRTA |
|---|---|---|
| Founded | 2021 | 2012 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 700.3M | 482.3M |
| IPO Year | 2020 | 2013 |
Fundamental Metrics
Financial Performance| Metric | TBLD | PRTA |
|---|---|---|
| Price | $21.85 | $9.43 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | 62.6K | ★ 387.4K |
| Earning Date | 01-01-0001 | 05-20-2026 |
| Dividend Yield | ★ 5.68% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $814,000.00 |
| Revenue This Year | N/A | $1,395.77 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $15.94 | $4.32 |
| 52 Week High | $23.02 | $15.14 |
Technical Indicators
Market Signals| Indicator | TBLD | PRTA |
|---|---|---|
| Relative Strength Index (RSI) | 46.81 | 54.91 |
| Support Level | $19.66 | $8.23 |
| Resistance Level | $23.02 | $9.59 |
| Average True Range (ATR) | 0.36 | 0.55 |
| MACD | -0.13 | 0.09 |
| Stochastic Oscillator | 10.20 | 66.40 |
Price Performance
Historical ComparisonAbout TBLD Thornburg Income Builder Opportunities Trust
Thornburg Income Builder Opportunities Trust is a diversified, closed-end management investment company. The Trust's investment objective is to provide current income. The Trust will seek to achieve its investment objective by investing, directly or indirectly, at least 80% of its Managed Assets.
About PRTA Prothena Corporation plc
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.